Document:

Amended and Restated Fifth Third Bancorp 1993 Stock Purchase Plan

 Exhibit 10(g) 
  
 Amended and Restated 
 Fifth Third Bancorp 
 1993 Stock Purchase Plan 
  
 The FIFTH THIRD BANCORP 1993 STOCK PURCHASE PLAN (the “Plan”) is hereby amended and restated effective January 1,
2004, pursuant to the direction of the Board of Directors of Fifth Third Bancorp, an Ohio corporation (“Company”). All capitalized terms not otherwise defined have the meaning set forth in Section 21 of this Plan. 
  

	 	1.	Purpose. The purpose of the Plan is to facilitate the purchase of the Company’s Common Stock by Company employees on terms and conditions that enhance the ability
of the employees to acquire a financial interest in the Company. The Company believes that employee ownership will promote productivity and encourage continued growth of the Company for the mutual benefit of the Company’s employees and
shareholders. 

  

	 	2.	Eligibility. Any full-time or part-time Employee of the Company or any Subsidiary who is at least eighteen years of age is eligible to participate in the Plan upon hire. The
Company’s Directors and executive officers (as defined by the rules and regulations of the Securities and Exchange Commission) are not eligible to participate in the Plan. 

  

	 	3.	Number of Shares of Common Stock Subject to Plan. The total number of shares of Common Stock that may be purchased under the Plan from and after January 1, 2004 shall
not exceed, in the aggregate, 1,000,000 shares of Common Stock (subject to adjustment as set forth below). If the number of shares of Common Stock outstanding is hereafter increased or decreased or changed into or exchanged for a different number or
kind of shares or other securities of the Company or of another corporation by reason of (a) any reorganization, merger, consolidation, recapitalization, reclassification, stock split, reverse stock split, combination of shares, or dividend payable
in shares of Common Stock, or (b) any other similar corporate transaction or event that affects the Common Stock such that an adjustment is determined, by the Board of Directors in its sole discretion, to be appropriate to prevent dilution or
enlargement of the benefits or potential benefits intended to be made available under the Plan, then the number of shares of Common Stock that may be purchased under this Plan shall be increased or decreased proportionately, and/or the different
kind of shares or other securities of the Company or of another corporation shall be substituted, as the case may be. 

  

	 	4.	Participation; Payroll Deduction. Any eligible Employee may become a participant in the Plan by completing and forwarding an authorization form to the Company at any time.
The authorization form will authorize and instruct the Company to deduct from the Employee’s Compensation each pay period a certain uniform dollar amount or uniform percentage of Compensation as specified by the Employee’s deduction
authorization. Payroll Deductions specified by percentage amount shall be in full percentages of Compensation. All Payroll Deductions must be at least $5.00 per pay period. The maximum Payroll Deduction for each Participant is 10 percent of the
Participant’s Compensation not to exceed $26,000 in any calendar year, provided the remaining Compensation of the Participant is sufficient to pay all payroll taxes, withholdings and any other payroll deductions. Payroll Deductions will be
effective with pay checks issued not later than the second pay date following receipt of the Participant’s Deduction authorization form. Thereafter, the Payroll Deduction will be made on each pay day for each applicable pay period. The
percentage or dollar amount of Payroll Deduction may be changed at any time and may be terminated at any time upon seven days’ prior notice to the Company’s Payroll Department from the Participant. 

  

	 	5.	Purchase of Common Stock. As soon as administratively possible, usually the next business day, the Company will remit to the Custodian the total of all Payroll Deductions
related to the immediately preceding pay period plus an additional amount payable by the Company equal to 15 percent of the total of all such payroll deductions. The Custodian will then apply such aggregate amount to the purchase in the open market,
through securities brokers/dealers who are members of the National Association of Securities Dealers, Inc. and who are duly licensed to buy and sell securities in each state in which there are Participants, as many whole shares of Common Stock as
may be purchased with such funds at the then prevailing Fair Market Value. Purchases of Common Stock will be completed as soon as administratively possible, usually the next business day, following receipt by the Custodian of such Payroll
Deductions. Failure to so timely purchase Common Stock will not subject the Custodian to reimbursement for any damages a Participant might suffer as a result of any delay in purchasing Common Stock. On at least an annual basis, the Custodian will
provide each Participant with a report as to the total number of shares of Common Stock allocated to his or her Account as of the last day of the reporting period. 

  

	 	6.	Custody; Delivery of Common Stock. Shares of Common Stock purchased under the Plan will be allocated to the respective Accounts of the Participants at the end of each pay
period in proportion to the contributions made by each Participant. Allocations will be made in full shares and in fractional shares to the sixth decimal place. The Custodian will hold shares for the Common Stock purchased in its nominee name until
any such shares are distributed to the Participant. Pursuant to section 11, upon written request of a Participant to the Company at any time, certificates representing all or part of the whole shares of Common Stock credited to the
Participant’s Account will be registered in the Participant’s name promptly and delivered to the Participant. Fractional shares will not be issued. Instead, fractional shares which have been credited to the Participant’s Account will
be converted in to cash by the Custodian at the then prevailing Fair Market Value on the sale date and promptly paid to the Participant in cash. 

 Exhibit 10(g) - continued 
  

	 	7.	Participant Rights in Common Stock. Each Participant will have all the rights of a shareholder of the Company with respect to the shares of Common Stock allocated to the
Participant’s Account. Such rights include without limitation the right to vote such shares and the right to receive all distributions of cash or other property with respect to such shares. In addition, appropriate adjustments will be made in
the number of shares credited to Participant’s Accounts to give effect to any stock dividends, stock splits, recapitalizations and similar changes. 

  

	 	8.	Dividend Reinvestment. Any cash dividends on the Common Stock, if and when declared and received by the Custodian with respect to shares held by the Plan, will be
credited to the Participants in proportion to the number of shares of Common Stock held by the Custodian for the Participant’s Account on the dividend record date. Any cash dividends received by the Custodian with respect to Common Stock held
under the Plan shall be applied toward the purchase for the Accounts of all Participants under the Plan of additional shares of Common Stock as soon as administratively possible, usually the next business day following the date of receipt of the
dividend.  

  

	 	9.	Voting. All shares, including fractional shares, of Common Stock in each Participant’s Account will be voted in accordance with proxy instructions duly delivered
to the Custodian by the respective Participant. Each Participant may instruct the Custodian how to vote the shares credited to the Participant’s Account and the Custodian will vote such shares accordingly. In the event no voting instructions
are provided, the Custodian shall vote the shares in the same proportion as the shares held under the Plan for which the Custodian receives voting instructions. 

  

	 	10.	No Interest. No Participant shall be entitled, at any time, to any payment or credit for interest with respect to or on the Payroll Deductions contemplated herein, or
on any other assets held hereunder for the Participant’s Account. 

  

	 	11.	Suspension of Payroll Deductions. Pursuant to section 6, a Participant may request certificates representing all or a portion of his or her whole shares in the Plan.
Upon such request, the Participant’s Payroll Deductions shall be suspended for a period of six months commencing on the date the certificates are issued to the Participant. Upon the expiration of the six-month suspension period, the Employee
may re-enroll in the Plan by submitting a new authorization form pursuant to section 6. Notwithstanding the foregoing, a Participant may request delivery of the shares in his or her Account for the purpose of exercising stock options, as granted by
Fifth Third Bancorp under its stock option plans, without becoming subject to a suspension period. As contemplated by Section 15, the Company’s Board of Directors has designated the Pension and Profit Sharing Committee the Administrator of the
Plan. The Administrator may from time to time also adopt other rules and procedures relating to partial terminations and/or other matters. 

  

	 	12.	Termination of Participation. A Participant’s participation in the Plan shall terminate on the Participant’s pay date for the pay period in which one of the
following occurs: (a) a Participant’s death or termination of employment; (b) discontinuance of the Plan by the Company; or (c) the Participant’s written election to terminate participation in the Plan is received by the Company. Upon
termination, certificates representing the total number of whole shares of Common Stock credited to the Participant’s Account will be issued in the Participant’s name or in the event of death in the name of the Participant’s legal
representative. The Custodian will deliver these certificates to the Participant or legal representative promptly. Fractional shares which have been credited to the Participant’s Account will be converted in to cash by the Custodian at the then
prevailing Fair Market Value on the sale date and promptly paid to the Participant in cash. If such request to terminate falls between the record date and payable date of a dividend or stock split, the certification and sale of fractional shares
will be processed after the payable date of the dividend. 

  

	 	13.	Designation of Custodian. The Company has designated Computershare Trust Company, Inc. as the Custodian subject to the Company’s right to terminate the
designation at any time and appoint a successor Custodian. 

  

	 	14.	Plan Expenses. The charges of the Custodian and all costs of maintaining records, administering the Plan and executing transfers by the Custodian will be borne by the
Company. 

  

	 	15.	Administration of Plan. The Board of Directors of the Company shall appoint the Pension and Profit Sharing Committee to serve as Administrator of the Plan. The duties
of the Administrator will be to announce the existence of the Plan; to provide employees with copies of the Plan and Payroll Deduction authorization instructions; to supervise Payroll Deductions; to forward Payroll Deductions to the Custodian; to
provide the Custodian with names and addresses of employees to facilitate communications regarding the Plan; and, if requested by the Custodian, to address and distribute communications to employees from the Custodian.

  
 The Board of Directors of the Company shall be
vested with full authority to make and interpret all rules and regulations as it deems necessary for the Administrator to administer the Plan. Any determination, decision or act of the Board of Directors with respect to any action in connection with
the construction, interpretation, or application of the Plan shall be final and binding upon all Employees, Participants, and all persons claiming under or through them. 
  

 Exhibit 10(g) - continued 
  

	 	16.	Limitation of Activities. Neither the Administrator nor any other employee or representative of the Company or a Subsidiary shall solicit Employees to participate in the
Plan, render investment advice of any kind or perform any function or activity relative to the Plan except the specified duties of the Administrator set forth in paragraph 15 above. All questions of Participants regarding administration of the Plan
shall be directed solely to the Administrator, and any questions relating to investment advice shall be directed solely to the Participant’s personal advisors. 

  

	 	17.	Term of Plan; Amendments. The Plan is effective on the date hereof and has no fixed expiration date, however, the Plan may be amended or discontinued by the Board of
Directors of the Company at any time. The Plan is intended to be a permanent program, but the Board or Directors of the Company shall have the right at any time to declare the Plan terminated completely as to it or as to any Subsidiary. No amendment
may make any change in any right previously granted which would adversely affect the rights of any Participant. 

  

	 	18.	Nonguaranty of Employment. The Plan is strictly a voluntary undertaking on the part of the Company and shall not constitute a contract between the Company or any
Subsidiary and any Employee, or consideration for an inducement or a condition of, the employment of an Employee. Nothing contained in the Plan shall give any Employee the right to be retained in the service of the Company or any Subsidiary or to
interfere with or restrict the right of the Company or any Subsidiary, which right is hereby expressly reserved, to discharge or retire any Employee at any time, with or without cause and with or without notice. Participation in the Plan will not
give any Employee any right or claim to any benefits hereunder except to the extent such right has specifically become fixed under the terms of the Plan. 

  

	 	19.	Governmental Approvals. Implementation and continuation of the Plan and the transactions contemplated hereby shall be subject to the Company obtaining any registration
or qualification under any federal or state law or obtaining the consent or approval of any governmental regulatory body which the Company shall determine, in its sole discretion, is necessary or desirable as a condition to, or in connection with,
the operation of the Plan. 

  

	 	20.	Section Headings. Section headings are provided herein for convenience only and are not to serve as the basis for interpretations or construction of the Plan.

  

	 	21.	Definitions: 

  

	 	(a)	Account – means that separate account maintained for each Participant under the Plan, which account shall be credited with the Participant’s Payroll
Deduction, charged for the purchases of Common Stock for that Participant under the Plan, and allocated that number of shares of Common Stock as have been acquired with Payroll Deductions contributed by the Participant. Each Account shall be the
property of the Participant for whom it is maintained and shall be nonforfeitable at all times. 

  

	 	(b)	Business Day – means a day in which the NASDAQ National Market System, or such other market system or exchange on which the Common Stock is then primarily traded,
is open for business. 

  

	 	(c)	Common Stock – means the common stock, no par value, of the Company. 

  

	 	(d)	Compensation – means the gross wages paid to the Employee during the period in question for services rendered by the Employee to the Company or any Subsidiary.
Compensation includes any wages or salary subject to a salary reduction arrangement under any cash or deferred profit sharing arrangement or cafeteria plan that is maintained by the Company or any Subsidiary and that is intended to be qualified
under I.R.C. Sections 401(k) or 125 respectively. Compensation does not include severance pay, moving allowance, or other noncash compensation. 

  

	 	(e)	Custodian – means that person or entity appointed by the Company in its sole discretion from time to time to take responsibility for safekeeping of the funds paid
in to the Plan and of the Common Stock purchased under the Plan. 

  

	 	(f)	Employee – means an individual who renders services to the Company or any Subsidiary as a common law employee or officer (i.e., a person whose wages from the
Company or any Subsidiary are subject to federal income tax withholding). A person rendering services to the Company or any Subsidiary as an independent contractor is not an Employee. 

  

	 	(g)	Fair Market Value – means the price(s) at which the Custodian is able to purchase Common Stock on the NASDAQ National Market System, or such other market system
or exchange on which the Common Stock is then primarily traded, on the purchase date. 

  

	 	(h)	Participant – means any Employee who is eligible to participate in the Plan and who authorizes Payroll Deductions under the Plan pursuant to Section 4 of the
Plan. 

  

	 	(i)	Payroll Deduction – means the amount or percentage of Compensation authorized by a Participant to be deducted from his Compensation under the Plan.

  

 Exhibit 10(g) - continued 
  

	 	(j)	Subsidiary – means any corporation, partnership, trade or business which is wholly owned, directly or indirectly, by the Company. 

  
 Executed as of January 1, 2004 
  

			
	FIFTH THIRD BANCORP
		
	By:	 	 /s/ George A. Schaefer, Jr.

	 	 	

	 	 	 George A. Schaefer, Jr.
 President & Chief Executive OfficerTermination and License Agreement

 Exhibit 10.201 
  
 Portions of this exhibit marked [*] are omitted and 
 are requested to be treated confidentially. 
  
 TERMINATION AND LICENSE AGREEMENT 
  
 THIS TERMINATION
AND LICENSE AGREEMENT (“Agreement”), effective as of December 18, 2003 (“Effective Date”), is made by and among Eli Lilly and Company, a corporation organized under the laws of the State of Indiana, having its principal place
of business at Lilly Corporate Center, Indianapolis, Indiana, 46285 (hereinafter “Lilly”), Pharmaceutical Product Development, Inc., a corporation organized under the laws of the State of North Carolina (hereinafter “PPD”),
GenuPro, Inc., a wholly-owned subsidiary of PPD, and a corporation organized under the laws of North Carolina (hereinafter “GenuPro”) and APBI Holdings, LLC, a wholly-owned subsidiary of PPD, and a limited liability company organized under
the laws of North Carolina (hereinafter “APBI Holdings”). (Each party to this Agreement is hereinafter referred to as a “Party”, or collectively, the “Parties.” All references to a Party shall be deemed to include that
Party’s Affiliates). 
  
 Recitals 
  
 A. Lilly, PPD and GenuPro are parties to a Development and License Agreement
effective as of May 22, 1998 (as amended to date, the “Development Agreement”). 
  

 B. Pursuant to the Development Agreement, Lilly has granted GenuPro certain intellectual property
licenses related to, among other things, a pharmaceutical composition known as Dapoxetine. 
  
 C. As permitted by the Development Agreement, GenuPro has sublicensed to Alza, Corporation (“Alza”) certain rights to develop and market Dapoxetine in exchange for which GenuPro is entitled to receive
certain milestone, royalty and other payments from Alza. Pursuant to the Development Agreement, Lilly is entitled to receive from GenuPro a portion of the payments received by GenuPro from Alza. 
  
 D. The parties now desire to, among other things, (i) terminate the
Development Agreement, (ii) transfer to APBI Holdings ownership of certain Lilly patents licensed to GenuPro pursuant to the Development Agreement and (iii) provide for an up-front cash payment to Lilly by APBI Holdings and a royalty based on Net
Sales of Dapoxetine (as defined herein below), all in accordance with the terms and conditions of this Agreement. 
  
 In consideration of the Recitals and the mutual covenants and promises contained herein, the Parties, intending to be legally bound, hereby agree as follows: 

 

 2 

 Article 1 
  

Definitions 
  
 As used herein, the following terms shall have the meaning indicated: 
  
 1.1 “Affiliate” means, with respect to a Party, any Person directly or indirectly controlling, controlled by, or under common control
with, such Party. For purposes of this definition, the term “controlled” (including the terms “controlled by” and “under common control with”) means the direct or indirect ability or power to direct or cause the
direction of management policies of a person or otherwise direct the affairs of such person, whether through ownership of equity, voting securities, beneficial interest, by contract or otherwise. 
  
 1.2 “Applicable Laws” means all applicable laws,
ordinances, rules and regulations of any kind whatsoever of any governmental (including international, foreign, federal, state and local) or regulatory authority, including, without limitation, all laws, ordinances, rules and regulations promulgated
by the U.S. Food and Drug Administration (“FDA”). 
  
 1.3 “Calendar Quarter” means the three (3) month period ending on March 31, June 30, September 30 or December 31. 
  
 1.4 “Calendar Year” means the twelve (12) month period ending on December 31. 
  
 1.5 “Compounds” means those compounds other than Dapoxetine
covered by a Valid Claim within the scope of the Licensed Patents. 
  

 3 

 1.6 “Confidential Information” means information received (whether disclosed in writing,
electronically, orally or by observation) by one Party (the “Receiving Party”) from the other Party (the “Disclosing Party”) that the Disclosing Party reasonably considers proprietary and confidential unless in each case
such information, as shown by competent evidence: 
  
 (a) was known to the Receiving Party or to the public prior to the Disclosing Party’s disclosure, as demonstrated by contemporaneous written records; 
  
 (b) became known to the public, after the Disclosing Party’s disclosure hereunder, other than through a
breach of the confidentiality provisions of this Agreement by the Receiving Party or any Person to whom such Receiving Party disclosed such information; 
  
 (c) was subsequently disclosed to the Receiving Party by a Person having a legal right to disclose, without any restrictions, such
information or data; or 
  
 (d) was developed by
the Receiving Party independent of the Disclosing Party’s Confidential Information. 
  
 1.7 “Damages” means any and all costs, losses, claims, demands for payment, government enforcement actions, liabilities, fines, penalties, expenses, court costs and 

  

 4 

 
reasonable fees and disbursements of counsel, consultants and expert witnesses incurred by a Party hereto (including any court-imposed interest in connection
therewith). 
  
 1.8 “Dapoxetine” [*] 

 
 1.9 “Data Exclusivity Period” means the period
during which the FDA (or, in countries other than the United States, an equivalent regulatory agency) prohibits reference, without the consent of the owner, to the clinical and other data that is contained in any application for marketing or
regulatory approval. 
  
 1.10 “Effective Date”
shall have the meaning set forth in the first paragraph hereof. 
  
 1.11 “GAAP” means U.S. generally accepted accounting principles, consistently applied. 
  
 1.12 “GenuPro Field” shall mean all therapeutic indications for use in humans (i.e. specifically excluding use in animals) within the
urogenital area, including primary urinary incontinence, urge, stress and mixed incontinence, urinary urgency, interstitial cystitis, neurogenic bladder, bladder sphincter dyssynergia and irritative symptoms of benign prostate hypertrophy,
hypoactive sexual desire, hyperactive sexual desire, impotence, retarded ejaculation, premature ejaculation, delayed orgasm and anorgasmia. 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 5 

 1.13 “GenuPro Improvements” means any inventions, patentable or not, information and/or
data relating to Compound and/or Dapoxetine, including clinical trial information, processes, formulations, modes of delivery and/or other data that are owned or controlled by GenuPro (i) in the case of Dapoxetine, during the term of this Agreement
and (ii) in the case of Compounds, as of the Effective Date. 
  
 1.14 “GenuPro Know-How” means any unpatented or unpatentable inventions, information, data, drawings, plans, specifications and designs relating to Dapoxetine or Compounds that is owned or controlled by GenuPro (i)
in the case of Dapoxetine, during the term of this Agreement and (ii) in the case of Compounds, as of the Effective Date including, in particular, any preclinical, clinical, toxicology, and/or ADME information or data. GenuPro Know-How shall not
include GenuPro Manufacturing Know-How or computer software. 
  
 1.15 “GenuPro Manufacturing Know-How” shall mean any unpatented or unpatentable information and/or data relating to Dapoxetine and/or Compounds necessary for one skilled in the art of large scale synthetic molecule
synthesis to synthesize and manufacture Dapoxetine and/or Compounds, including processes therefore, that is owned or controlled by GenuPro (i) in the case of Dapoxetine, during the term of this Agreement and (ii) in the case of Compounds, as of the
Effective Date. 
  

 6 

 1.16 “Licensed Patents” means those patents and patent applications listed in Exhibit
A attached hereto and any resulting issued patents arising out of or that may claim priority to such patents and patent applications and that arise from inventions disclosed therein and all national stage applications, divisionals, continuations
and continuations in part that may arise out of or may claim priority to these patents and applications and any reissues, reexaminations, extensions and supplemental protection certificates arising from such patents. 
  
 1.17 “Lilly Improvements” means any inventions, patentable
or not, information and/or data relating to Dapoxetine including, without limitation, processes, formulations, modes of delivery and/or other data, that are owned or controlled by Lilly during the term of this Agreement. 
  
 1.18 “Lilly Manufacturing Know-How” shall mean any
unpatented or unpatentable information and/or data relating to Dapoxetine necessary for one skilled in the art of large scale synthetic molecule synthesis to synthesize and manufacture Dapoxetine, including processes therefore, that is owned or
controlled by Lilly, during the term of this Agreement. 
  
 1.19 “Lilly Know-How” means any unpatented or unpatentable inventions, information, data, drawings, plans, specifications and designs relating to Dapoxetine owned or controlled by Lilly during the term of this Agreement
including, in particular, 

  

 7 

 
any preclinical, clinical, toxicology and/or ADME information or data. Lilly Know-How shall not include Lilly Manufacturing Know-How or computer software.

  
 1.20 “Lilly Field” shall mean all uses except
for the GenuPro Field. 
  
 1.21 “Net Sales”
means, with respect to Product, the total amount billed or invoiced by any Permitted Seller to unrelated Third Persons for sales of Product in the Territory less the following deductions calculated in accordance with GAAP, consistently applied:

  
 (i) trade, cash and quantity discounts
actually taken on such; 
  
 (ii) taxes on sales
(such as sales or use taxes) to the extent added to the sale price and set forth separately as such in the total amount invoiced; 
  
 (iii) freight, insurance and other transportation charges to the extent added to the sale price and set forth separately as such in the
total amount invoiced; and 
  
 (iv) reserves for
amounts to be repaid or credited by reason of rejections, defects, recalls or returns or because of retroactive price reductions, chargebacks, rebates or commissions, made in accordance with generally accepted accounting principles and Permitted
Seller’s accounting policies. 
  
 Sales between GenuPro and
its Affiliates and licensees and Permitted Sellers and their Affiliates and licensees shall not be treated as Net Sales hereunder. 
  

 8 

 In the event the Product is sold by the Permitted Seller as part of a combination product, the Net Sales
of the Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales (as defined above) of the combination product by the fraction A/(A+B), where A is Permitted Seller’s published sales price of the
Product when sold separately in finished form and B is Permitted Seller’s published sales price of the other product(s) sold separately in finished form. In the event that such published sales price cannot be determined for both the Product and
the other product(s) in combination, Net Sales for purposes of determining royalty payments shall be mutually agreed by the parties based on the relative value contributed by each component, and such agreement shall not be unreasonably withheld.

  
 Such Net Sales shall be determined from the books and records
of the Permitted Seller, maintained in accordance with GAAP, consistently applied. For purposes of this definition Net Sales shall be deemed to have occurred upon invoicing of such Product or if not invoiced, then when delivered, shipped, or paid
for, whichever comes first. Further, in determining such amounts, the Permitted Seller will use its then current standard procedures and methodology. The translation of foreign currency sales into U.S. Dollars will be based on the exchange rates
published in the Wall Street Journal on the last business day of the applicable Calendar Quarter. For purposes of calculating Net Sales, in the case of a sale or other disposal of Product for value other than in an arm’s-length transaction
exclusively for money, such as barter or counter-trade, the amount of such sale shall be calculated using the fair market value of such Product (if higher than the stated sales price) in the country of disposition. 
  

 9 

 1.22 “Permitted Seller” means APBI Holdings, GenuPro and any assignee, licensee or
sublicensee having the right to sell Product, including without limitation, Alza and any permitted assignee, licensee or sublicensee of Alza, but excluding Lilly. 
  
 1.23 “Person” means a natural person, a corporation, a partnership, a trust, a joint venture,
a limited liability company, any governmental authority, or any other entity or organization. 
  
 1.24 “Product” means any human pharmaceutical composition or preparation, in any dosage strength or size, for any mode of administration, containing Dapoxetine. 
  
 1.25 “Royalty Term” means, with respect to each country in
which the Product is sold, on a Product by Product basis, that time period beginning on the first sale of Product in such country and expiring, on a country-by-country basis, on the later of the following: 
  
 (a) the [*] anniversary of the date of first
commercial sale of Product in such country; 
  
 (b) the expiration in such country of the last-to-expire Licensed Patent with a Valid Claim; or 
  
 (c) the expiration of any applicable Data Exclusivity Period in such country. 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 10 

 1.26 “Termination Date” means the date on which Lilly receives the payment provided for
in Section 3.1(a). 
  
 1.27 “Territory” means all
countries of the world. 
  
 1.28 “Third Person”
means Persons other than the Parties. 
  
 1.29
“Valid Claim” means a claim of an issued and unexpired Licensed Patent in a country which: (i) but for this Agreement, would be infringed by the manufacture, importation, use, offer for sale or sale or other disposition of Product by
or on behalf of GenuPro, APBI Holdings or another Permitted Seller, (ii) has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the
time allowed for appeal, and (iii) has not been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 
  
 Article 2 
  
 Termination and Assignment 
  
 2.1 Termination of Development Agreement. Lilly, PPD and GenuPro hereby terminate the Development Agreement effective as of the Termination Date. As of the Termination Date, the Development
Agreement shall have no further force or 

  

 11 

 
effect and no party thereto shall have any further right or obligation thereunder except that: 
  
 a. Termination of the Development Agreement shall not release or discharge any party from the performance of
any obligation, the payment of any debt or responsibility for any liability which may have accrued prior to the Termination Date and remains to be performed, paid or discharged, as of the Termination Date. However, following the Termination Date, no
further obligations under the Development Agreement shall by incurred by any party, except as specifically provided in subparagraphs b and c below. 
  
 b. The obligations of confidentiality set forth in Section 10.1 and 10.2 of the Development Agreement shall continue in effect for the
period stated therein. 
  
 c. The obligations to
indemnify set forth in Sections 14.03(a) of the Development Agreement shall continue in effect indefinitely, but only with respect to any cause of action arising prior to the Termination Date. 
  
 Without limiting the generality of the foregoing, following the Termination
Date, Lilly shall have no further obligation to provide any assistance of any type to PPD or GenuPro in connection with the research, development, manufacturing or sale of Dapoxetine, Product or any other product. 
  

 12 

 2.2 Assignment of Licensed Patents. Concurrently with the execution of this
Agreement, Lilly shall execute a Patent Assignment Agreement in the form attached hereto as Exhibit B transferring to APBI Holdings ownership of the Licensed Patents effective as of the Termination Date. 
  
 Article 3 
  
 Consideration 
  
 3.1 Payments from APBI Holdings to Lilly. Subject to and upon the terms and conditions of this Agreement, APBI Holdings shall
make the following payments to Lilly: 
  
 (a)
Upfront Payment to Lilly. Concurrently with the execution of this Agreement, APBI Holdings shall transfer to Lilly by Federal Reserve wire transfer to an account designated by Lilly the sum of sixty-five million U.S. dollars ($65,000,000) in
immediately available funds. 
  
 (b) Royalty
Payments from APBI Holdings to Lilly. APBI Holdings shall pay to Lilly a royalty of five percent (5%) on Net Sales of Product in excess of $800 million in annual Net Sales for any Calendar Year during the Royalty Term. Net Sales of all
presentations and forms of Product shall be aggregated for purposes of determining annual 

  

 13 

 
Net Sales. APBI Holdings shall pay royalties due hereunder concurrently with the remittance of the royalty report required by Section 3.2 
  
 (c) Third Party Payments. APBI Holdings shall pay
when due any and all milestone, royalty and other similar obligations Lilly might be obligated to pay to a Third Party pursuant to an agreement between Lilly and such Third Party covering rights relating to any Product in accordance with the terms
and conditions set forth in such agreement between Lilly and such Third Party. Lilly hereby represents and warrants to APBI Holdings that to the best of its knowledge, no agreements imposing such Third Party obligations exist as of the Effective
Date. 
  
 (d) Form of Payment. All amounts
payable to Lilly under Section 3.1 shall be paid in U.S. dollars by Federal Reserve electronic wire transfer in immediately available funds to an account designated in writing by Lilly (unless otherwise instructed by Lilly in writing). 

 
 3.2 Record Retention, Royalty Reports, and Royalty Payment
Schedule. APBI Holdings shall keep (and shall require Permitted Sellers to keep) complete and accurate books and records that are necessary to ascertain and verify royalty payments owed to Lilly. Such records shall be kept in accordance with
GAAP and APBI Holdings’ or its Permitted Sellers usual internal practices and procedures, consistently applied. GenuPro shall furnish Lilly with a quarterly report on Net Sales within sixty (60) days of the end of the first three Calendar
Quarters in each Calendar Year and within seventy-five (75) days of the end of the last Calendar Quarter of each Calendar Year. Such report shall include a written report detailing: (i) the Net Sales for the previous Calendar 

  

 14 

 
Quarter, broken down by country and between APBI Holdings, GenuPro and any Permitted Sellers, (ii) the royalty payment that is due and payable under Section
3.01(b) hereof if any, and (iii) the basis for calculating such Royalty Payment. APBI Holdings will mail such report to the attention of: Eli Lilly and Company, Lilly Royalty Administration in Finance, Lilly Corporate Center, Indianapolis, Indiana,
46285. The amount of royalty payment due to Lilly shall be paid by APBI Holdings concurrently with the remittance of each royalty report. 
  
 3.3 Audits. APBI Holdings will keep full and accurate books and records relating to the performance required of it under this Agreement.
Lilly will have the right, during regular business hours and upon reasonable advance notice, to have such books and records of APBI Holdings audited no more than one (1) time per Calendar Year so as to verify the accuracy of the information
previously reported to Lilly. Lilly will, for purposes of such audit, utilize the services of an independent certified public accounting firm reasonably acceptable to APBI Holdings (which need not be APBI Holdings then current independent auditing
firm.) Such audit may cover the two (2) calendar years preceding the date of the request for such audit. Such accountants will keep confidential any information obtained during such audit and will report to Lilly only their conclusions. The cost of
such audit will be borne by Lilly; however, if the result of such audit shows that the amount owed to Lilly is [*] percent [*] or more greater than the amount paid, the cost of the audit will be borne by
APBI Holdings. Within thirty (30) days after Lilly and APBI Holdings have received a copy of an audit report, APBI Holdings or Lilly, as  
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 15 

 appropriate, will compensate the other Party for payment errors or omissions revealed by the audit. APBI Holdings will
include in all future licenses of Licensed Patents, and any other agreements enabling a Third Person to be a Permitted Seller, an audit provision substantially similar to the foregoing requiring such Permitted Seller to keep full and accurate books
and records relating to the Product and granting APBI Holdings the right to have an independent public accounting firm audit the accuracy of the information reported by the licensee in connection therewith. At Lilly’s request, APBI Holdings
shall invoke any rights it may have to audit a Permitted Seller and make the results of such audit available to Lilly promptly. 
  
 3.4 Taxes And Currency. Any and all taxes levied on any payments under this Agreement shall be the liability of and paid by Lilly. If laws or
regulations require the withholding of such taxes, the taxes will be deducted by APBI Holdings from the payment and remitted by APBI Holdings to the proper tax authority, provided that APBI Holdings will furnish Lilly with a copy of the official tax
receipt on such withholdings as soon as practicable after such withholding, and give Lilly such assistance as may be reasonably necessary to enable or assist Lilly to claim exemption or take credit therefrom, provided that Lilly reimburses APBI
Holdings for any out of pocket expenses incurred by it in providing such assistance. Proof of payment shall be provided to Lilly within sixty (60) days after payment. APBI Holdings will reasonably cooperate with Lilly in pursuing tax refunds, if
such refund is appropriate in Lilly’s determination, provided that Lilly reimburses APBI Holdings for any out of pocket expenses incurred by it in providing such assistance. 
  

 16 

 3.5 Late Payment. Any amounts not paid APBI Holdings when due under this Agreement will be
subject to interest from and including the date payment is due through and including the date upon which Lilly has collected the funds in accordance herewith at a rate equal to the lesser of (i) the sum of [*] percent [*]
plus the prime rate of interest quoted in the Money Rates (or equivalent) section of the Wall Street Journal, calculated daily on the basis of a three hundred sixty (360) day year, or (ii) the maximum interest rate allowed by law. 

 
 3.6 Guarantee of Payment. PPD hereby unconditionally
guarantees the obligations of APBI Holdings to make payment to Lilly as provided herein. Such guarantee shall survive any transfer of ownership of APBI Holdings or any of its assets or the assignment by APBI Holdings of any of its obligations under
this Agreement. 
  
 Article 4 
  
 Licenses 
  
 4.1 License Grants to Lilly. APBI Holdings and GenuPro, as applicable, hereby grants to Lilly: 
  
 (a) A perpetual, non-cancelable, fully paid-up, royalty
free, exclusive (even as to APBI Holdings) license, with right to sublicense, under the GenuPro Know-How, GenuPro Improvements, GenuPro Manufacturing Know-How, and Licensed 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 17 

 Patents to make, have made, use, sell, offer for sale, and import Dapoxetine and Product in the Territory
solely for use in the Lilly Field. 
  
 (b) A
perpetual, non-cancelable, fully paid-up, royalty free, non-exclusive license to use GenuPro Know-How, GenuPro Improvements, GenuPro Manufacturing Know-How and Licensed Patents for internal research purposes (which shall include the right to use
with Lilly research partners) in the GenuPro Field. 
  
 (c) A perpetual, non-cancelable, fully paid-up, royalty free, exclusive (even as to APBI Holdings) license, with right to sublicense, under the GenuPro Know-How, GenuPro Improvements, GenuPro Manufacturing Know-How and Licensed Patents to
make, have made, use, sell, offer for sale, and import Compounds in the Territory for use in the GenuPro Field and the Lilly Field. 
  
 4.2 License Grants to GenuPro. Lilly hereby grants to GenuPro and APBI Holdings an exclusive (even as to Lilly) license, with right to
sublicense, under the Lilly Know-How, Lilly Manufacturing Know-How and Lilly Improvements to make, have made, use, sell, offer for sale, and import Dapoxetine and Products in the Territory solely for use in the GenuPro Field. 
  
 4.3 Notification of Sublicenses. In the event either APBI Holdings,
GenuPro or Lilly sublicenses any of the license rights granted hereunder other than to an Affiliate, it shall promptly advise the others in writing of the identity of the sublicensee.  
  

 18 

 Article 5 
  

Intellectual Property Matters 
  
 5.1 Intellectual Property Maintenance. Licensed Patents shall be filed, prosecuted and maintained worldwide by APBI Holdings or a Third
Person patent counsel designated by APBI Holdings . Lilly will waive any conflict of interest that may arise as a result of such counsel representing the interests of both licensee and licensor. APBI Holdings shall have the ultimate responsibility
for and control over such matters and shall bear all expenses incurred in filing, prosecuting and maintaining Licensed Patents. APBI Holdings or its designee shall keep Lilly reasonably informed of the filing, prosecution and maintenance of Licensed
Patents, and shall furnish to Lilly copies of substantive documents (e.g., office actions, responses, etc.) relevant to any such efforts in advance with ten (10) working days for Lilly to review and provide comments on such documents, and shall use
its reasonable efforts to incorporate the comments and suggestions of Lilly, if any. If APBI Holdings decides to allow any Licensed Patent to lapse without entry of the national phase in one or more countries designated in such application, or if
APBI Holdings wishes to abandon or allow to lapse any Licensed Patent, APBI Holdings shall notify Lilly in writing not less than thirty (30) days prior to taking such action, and if Lilly so requests, APBI Holdings shall transfer and assign to Lilly
its rights under the patent or patent application in the country or countries so affected and Lilly may assume control of the same at Lilly’s sole expense. In the event that APBI Holdings receives a restriction requirement from a patent office
for a Licensed Patent that restricts out patent claims related only to Compounds, APBI Holdings shall 

  

 19 

 
inform Lilly in a timely manner to enable Lilly to pursue such patent claims independently of APBI Holdings, in which Lilly shall be solely responsible for
all costs and expenses related thereto. 
  
 5.2
Improvements. Each party shall promptly notify the others upon the making conceiving or reducing to practice of any Lilly Improvement or GenuPro Improvement. Lilly shall own all Lilly Improvements and bear all patent prosecution costs related
thereto and GenuPro shall own all GenuPro Improvements and bear all patent prosecution costs related thereto. 
  
 5.3 No Fiduciary Relationship. The Parties hereby expressly agree and acknowledge that they do not intend to create any type of fiduciary
relationship as a result of the intellectual property maintenance provisions set forth in this Agreement. Without limitation or condition of the foregoing, Lilly agrees to provide APBI Holdings’ agent with any and all powers of attorney and
other instruments necessary for APBI Holdings to conduct the filing, prosecution or maintenance of the Licensed Patents as provided in this Agreement, and Lilly acknowledges that any such power of attorney will make APBI Holdings’ agent an
attorney-in-fact for Lilly with respect to the matter specified in the power of attorney or other instrument but will not create an attorney/client relationship or any other fiduciary relationship between Lilly and APBI Holdings’ agent except
to the extent the Parties share a community of interest hereunder and under law. 
  

 20 

 5.4 Enforcement of Intellectual Property Rights. APBI Holdings and Lilly will promptly notify the
other of any infringement or suspected infringement of Licensed Patents, that may come to its notice, and will provide the other party with information with respect thereto. If a Third Person infringes any intellectual property rights relating
solely to the Licensed Patents, APBI Holdings will have the first right (but not the obligation) to pursue any and all injunctive relief, and any or all compensatory and other remedies and relief (collectively, “Remedies”), against such
Third Person. Should APBI Holdings determine not to pursue Remedies with respect to any such intellectual property within sixty (60) days after receipt of written notice from Lilly requesting APBI Holdings to do so, then Lilly will have the right
(but not the obligation) to pursue Remedies against such Third Person; provided, however, that such written notice from Lilly to APBI Holdings must state that APBI Holdings must take action on the subject matter contained within the notice within
sixty (60) days of APBI Holding’s receipt thereof.  
  
 5.5 Assistance and Cooperation. If a Party pursues Remedies hereunder, the other Party will use all reasonable efforts to assist and cooperate with the Party pursuing such Remedies. Each Party will bear its own costs and expenses
relating to such pursuit. Any damages or other amounts collected will be distributed, first, to the Party that pursued Remedies to cover its out of pocket costs and expenses; and second, to the other Party to cover its out of pocket costs and
expenses, if any, relating to the pursuit of such Remedies; and any remaining amount will be distributed [*] to the Party that pursued the Remedies and [*] to the other Party. 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 21 

 5.6 Settlement of Litigation. No settlement, consent judgment or other final disposition of
an action for infringement or validity of patent claims that relate in any material way to Compounds or the use of Dapoxetine in the Lilly Field, whether composition or method claims, may be entered into as to any Licensed Patent without
Lilly’s prior written consent, which consent shall not be unreasonably withheld.  
  
 5.7 Infringement of Third Person Rights. If a Third Person institutes a patent, trade secret or other infringement suit against Lilly, APBI Holdings, GenuPro or a Permitted Seller during the term of this
Agreement, alleging that the manufacture, marketing, sale, use or importation of Product (in the case of APBI Holdings, GenuPro or a Permitted Seller) or Compound (in the case of Lilly) infringes one or more patent or other intellectual property
rights held by such Third Person (a “Claim”), then APBI Holdings or GenuPro will have the first right (but not the obligation), at its sole expense, to assume direction and control of the defense of such Claims as they relate to Product,
and Lilly shall have the first right (but not the obligation) as they relate to Compound. A Claim received by APBI Holdings or GenuPro related to a Compound shall be forwarded immediately to Lilly, and a Claim received by Lilly related to a Product
shall be forwarded immediately to GenuPro. In the event APBI Holdings or GenuPro is deemed to be a necessary party for any suit relating to Compound or Lilly requests any assistance from APBI Holdings or GenuPro, Lilly shall pay all out of pocket
expenses, including attorney’s fees, incurred by APBI Holdings or GenuPro. Should either Party determine not to pursue the defense of a particular Claim, such Party shall notify the other Party within five (5) days after notice from the other
Party 

  

 22 

 
requesting it to do so, then the requesting Party will have the right (but not the obligation), at its sole expense, to assume direction and control of such
claims. Neither Party will have the right to settle or otherwise dispose of any such claim without the consent of other, which consent will not be unreasonably withheld. In the event Lilly is deemed to be a necessary party for any suit relating to
Dapoxetine or APBI Holdings requests any assistance from Lilly, APBI Holdings shall pay all out of pocket expenses, including attorney’s fees, incurred by Lilly. 
  
 5.8 Patent Reporting. Within sixty (60) days after each Calendar Year, APBI Holdings shall provide Lilly with a
written report describing the status of all Licensed Patents, including the patent country, patent and application numbers, filing date, issue date, expiration date, and any other relevant information requested by Lilly. Such report shall be mailed
to Eli Lilly and Company, Lilly Royalty Administration in Finance, Lilly Corporate Center, Indianapolis, Indiana, 46285 with a copy to the General Patent Counsel. 
  
 5.9 Patent Cooperation. Each Party hereby agrees: 
  
 (a) to make its employees, agents and consultants reasonably available to the other Party at the other
Party’s expense to the extent reasonably necessary to enable the Party responsible for prosecuting the Licensed Patents to undertake preparation, filing, prosecution and maintenance of the Licensed Patents; 
  
 (b) to cooperate, if necessary and appropriate, with the
other Party in gaining patent term extensions wherever applicable to Licensed Patents; and 
  

 23 

 (c) to endeavor to reasonably coordinate its efforts with the other Party to minimize or
avoid interference with the preparation, filing, prosecution and maintenance of the Licensed Patents. 
  
 5.10 Patent Marking. To the extent permitted by Applicable Laws, Lilly agrees to mark, and to cause any Affiliate or sublicensee to mark,
Lilly’s Products (through a marking on containers, packaging or labels, or an Orange Book or like listing) made, sold, or otherwise disposed of by it or them with any notice of patent rights necessary or desirable under Applicable Law to enable
patent rights to be enforced to their full extent in any country where such Lilly’s Products are to be sold. 
  
 5.11 Trademarks. GenuPro or its licensee shall own all trademarks developed by GenuPro or its licensee used to identify a Product sold by GenuPro.

  
 Article 6 
  
 Confidentiality 
  
 6.1 Confidential Information. The Parties agree that, unless the
Receiving Party (as defined in the definition of “Confidential Information” in Article 1) obtains the prior written consent of the Disclosing Party (as defined in the definition of “Confidential Information” in Article 1), at all
times during the term of this Agreement and for a [*] - year period following its expiration or earlier termination, the Receiving Party will keep completely confidential, will not publish or otherwise disclose and will not use directly or

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 24 

 indirectly for any purpose other than as contemplated by this Agreement any such Confidential Information of the
Disclosing Party, whether such Confidential Information was received by the Receiving Party prior to, on or after the Effective Date. 
  
 6.2 Limited Disclosure Permitted. Each Party may disclose Confidential Information to the extent that such disclosure is: 
  
 (a) made in response to a valid order or subpoena of a court
of competent jurisdiction or other governmental body of a country or any political subdivision thereof of competent jurisdiction; provided, however, that the Receiving Party will first have given notice to the Disclosing Party and given the
Disclosing Party a reasonable opportunity to quash such order or subpoena and to obtain a protective order requiring that the Confidential Information and documents that are the subject of such order or subpoena be held in confidence by such court
or governmental body or, if disclosed, be used only for purposes for which the order or subpoena was issued; provided further, however, that if a disclosure order or subpoena is not quashed or a protective order is not obtained, the Confidential
Information disclosed in response to such court or governmental order or subpoena will be limited to that information that is legally required to be disclosed in such response to such court or governmental order or subpoena; 
  
 (b) otherwise required by law, in the opinion of legal
counsel to the Receiving Party, provided that the Receiving Party shall advise the Disclosing Party in 

  

 25 

 
advance of any such disclosure and cooperates with the Disclosing Party in limiting the disclosure required. 
  
 (c) made by the Receiving Party to the governmental or
regulatory authority as required to obtain or maintain marketing approval for the Product, provided that reasonable effort will be taken to ensure confidential treatment of such information; 
  
 (d) made by the Receiving Party to a Third Person as may be
necessary or useful in connection with the manufacture, development and commercialization of the Product or Compound, provided that the Receiving Party will in each case obtain from the proposed Third Person recipient a written confidentiality
agreement containing confidentiality and non-use obligations no less onerous than those set forth in this Agreement; 
  
 (e) made by the Receiving Party to a United States or foreign tax authority; 
  
 (f) made by the Receiving Party to its representatives;
provided, however, that: (i) each such representative has a need to know such Confidential Information for purposes of this Agreement, (ii) the Receiving Party informs each representative receiving Confidential Information of its confidential
nature, and (iii) the Receiving Party will be responsible for any breach of this Article 7 by any of its representatives to the same extent as if the breach were by the Receiving Party; 
  

 26 

 (g) made by a Receiving Party or any representative of the Receiving Party in the filing
or publication of patents or patent applications relating to Licensed Patents, or any invention relating to a Compound or Product, to the extent such disclosure in the filing or publication of the patent or patent application is reasonably necessary
for support of the patent or patent application; 
  
 (h) made by a Receiving Party in order to comply with applicable securities law disclosure requirements. 
  
 6.3 Notification. The Receiving Party will notify the Disclosing Party immediately, and cooperate with the Disclosing Party as the Disclosing Party
may reasonably request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s Confidential Information. 
  
 6.4 Disclosure of Agreement. Except as contemplated herein, neither Party shall disclose this Agreement (nor a redacted version thereof) to
any Third Person without the prior written consent of the other Party. Without limitation, these prohibitions apply to press releases, annual reports, prospectuses, public statements, educational and scientific conferences, promotional
materials, governmental filings and discussions with public officials, securities analysts, investors and the media. However, subject to the requirements for review and approval that follow, this provision does not apply to a disclosure regarding
this Agreement, which counsel to a Party has advised is required by Applicable Laws, to regulatory agencies such as the FDA, Securities and 

  

 27 

 
Exchange Commission (“SEC”), Federal Trade Commission or Department of Justice. This includes requests for a copy of this Agreement or related
information by tax authorities. 
  
 If any Party to this Agreement
determines a release of information regarding the existence or terms of this Agreement is required by Applicable Laws, prior to any release of such information, that Party will notify the other Party in writing as soon as practical and provide as
much detail as possible in relation to the disclosure required and, where possible under Applicable Laws, will endeavor in good faith to provide the other Party with a minimum of five (5) business days to review the proposed public statement. The
Parties will then discuss what information, if any, will actually be released and that Party shall obtain the other Party’s prior written consent or conduct any actions it may reasonably take to prevent or limit the requested disclosure. In
addition, Lilly shall have the right to review and comment on a redaction of this Agreement required by the SEC or other agencies and PPD shall use good faith in taking Lilly’s comments into account prior to releasing the redaction to the SEC
or such agency. 
  
 Notwithstanding anything herein to the contrary, any Party to
this Agreement (and each employee, representative, or other agent of such party) may disclose to any and all persons, without limitation of any kind, and in accordance with Treas. Reg. § 1.6011-4(b)(3), the tax treatment and tax structure of
the transactions, not including confidential financial terms, contemplated by this Agreement and all materials of any kind (including opinions and other tax analyses) that are provided to it relating to such tax treatment and 

  

 28 

 
tax structure. PPD shall be required to obtain the consent of Lilly prior to issuing a press release announcing this Agreement and the transaction
contemplated hereby. 
  
 6.5 Survival. The
confidentiality and non-use obligations of this Article shall survive the termination or expiration of this Agreement. 
  
 Article 7 
  
 Representations, Warranties, Covenants, and Disclaimers 
  
 7.1 No Debarment. Each Party represents and warrants to the other that it will comply at all times with the provisions of the Generic Drug
Enforcement Act of 1992 and upon request each Party will certify in writing to the other Party that neither such Party, its employees, nor any Person providing services for such Party under this Agreement has been debarred under the provisions of
such Act. 
  
 7.2 Corporate Existence. As of the Effective
Date, each Party represents and warrants to the other that it is a company duly organized, validly existing, and, if relevant in its jurisdiction of formation, in good standing under the laws of the jurisdiction in which it is formed. 
  

 29 

 7.3 Authority to Execute and Perform. As of the Effective Date, each Party represents and warrants
to the other that it: 
  
 (i) has the power and
authority and the legal right to enter into this Agreement and perform its obligations hereunder; 
  
 (ii) has taken all necessary action, corporate or otherwise, on its part required to authorize the execution and delivery of this
Agreement; and 
  
 (iii) has duly executed and
delivered this Agreement, which constitutes a legal, valid, and binding obligation of it and which is enforceable against it in accordance with this Agreement’s terms. 
  
 7.4 Authority to Transfer Licensed Patents. Lilly represents and warrants to APBI Holdings that Lilly is the
owner of all right, title and interest in the Licensed Patents and is transferring the Licensed Patents to APBI Holdings free and clear of all liens, encumbrances, licenses, options and similar rights, other than those created by this Agreement.
This provision shall not constitute a representation or warranty that the Licensed Patents are valid or enforceable or that practice of the Licensed Patents would not violate the intellectual property rights of others. 
  
 7.5 Authority to Grant Licenses. Each Party hereby represents
and warrants to the other that to the best of its knowledge, it has the full right and power to grant the licenses set forth herein, in the manner and to that extent provided herein, free and clear of any adverse assignment, grant or other
encumbrance inconsistent with such grant, except 

  

 30 

 
that, in the case of licenses granted by Lilly, such licenses are subject to the exceptions listed in Schedule 11.01 to the Development Agreement. In
addition, neither Party makes any representation or warranty that exercise of the rights granted hereunder would not violate the intellectual property rights of Third Persons. 
  
 7.6 DISCLAIMER OF LILLY IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE, LILLY MAKES NO
REPRESENTATION OR WARRANTY AS TO THE LICENSED PATENTS, LILLY KNOW-HOW, LILLY IMPROVEMENTS OR LILLY MANUFACTURING KNOW-HOW, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE, OR OTHERWISE, INCLUDING ANY ASSURANCE THAT THE LICENSED
PATENTS ARE VALID OR THAT THE MANUFACTURE OR SALE OF PRODUCTS WILL NOT VIOLATE ANY INTELLECTUAL PROPERTY RIGHTS OF ANY PERSON. LILLY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES INCLUDING WARRANTIES OF MERCHANTABILITY AND OF
FITNESS FOR A PARTICULAR PURPOSE. Without limiting the foregoing, APBI Holdings acknowledges that it has not and is not relying upon any implied warranty of merchantability or of fitness for a particular purpose or otherwise, or upon any
representation or warranty whatsoever as to the prospects (financial, regulatory or otherwise), validity, or likelihood of success of Product after the Effective Date. 
  

 31 

 7.7 DISCLAIMER OF APBI HOLDINGS, GENUPRO AND PPD IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED
IN THIS ARTICLE, APBI HOLDINGS, GENUPRO AND PPD MAKE NO REPRESENTATION OR WARRANTY AS TO THE LICENSED PATENTS, GENUPRO KNOW-HOW, GENUPRO IMPROVEMENTS OR GENUPRO MANUFACTURING KNOW-HOW, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW,
STATUTE, OR OTHERWISE, INCLUDING ANY ASSURANCE THAT THE LICENSED PATENTS ARE VALID OR THAT THE MANUFACTURE OR SALE OF PRODUCTS BY LILLY WILL NOT VIOLATE ANY INTELLECTUAL PROPERTY RIGHTS OF ANY PERSON. APBI HOLDINGS, GENUPRO AND PPD SPECIFICALLY
DISCLAIM ANY AND ALL IMPLIED OR STATUTORY WARRANTIES INCLUDING WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE. Without limiting the foregoing, Lilly acknowledges that it has not and is not relying upon any implied warranty of
merchantability or of fitness for a particular purpose or otherwise, or upon any representation or warranty whatsoever as to the prospects (financial, regulatory or otherwise), validity, or likelihood of success of a Product sold by Lilly after the
Effective Date. 
  
 7.8 DISCLAIMER OF INCIDENTAL AND
CONSEQUENTIAL DAMAGES. NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, INCLUDING BUT NOT LIMITED TO LOST PROFITS ARISING FROM OR 

  

 32 

 
RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR
RESTRICTS THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY. 
  
 7.9 DILIGENCE. Neither Party shall have any obligation, either express or implied, to develop, market or sell any Product or Compound, or to otherwise exploit or commercialize any licenses granted hereunder. 
  
 Article 8 
  
 Indemnification 
  
 8.1 Indemnification. 
  
 (a) GenuPro’s Obligation. Except to the extent such Damages are due to negligence, gross negligence or willful misconduct by
Lilly, or its officers, directors, employees or agents, GenuPro shall defend, indemnify and hold harmless Lilly and its officers, directors, employees and agents against any and all Damages resulting from or arising out of: 
  
 (i) any breach of any representation or warranty made by
GenuPro, APBI Holdings or PPD in this Agreement or any documents executed in connection herewith; 
  
 (ii) the handling, possession, development, marketing, distribution, promotion, sale or use of Product by APBI Holdings, GenuPro or a
Permitted Seller; 
  

 33 

 (iii) any product liability or other claim arising out of any allegation of injury caused
by any person’s use of Product which Product is distributed or sold by APBI Holdings, GenuPro or any Permitted Seller or their respective agents or contractors; 
  
 (iv) the exercise of any right(s) under the Licensed Patents or Lilly Know-How, Lilly Improvements or Lilly
Manufacturing Know-How, by APBI Holdings, GenuPro, its Permitted Seller and any other sublicensees; or 
  
 (v) APBI Holdings’ or GenuPro’s failure to comply in all material respects with Applicable Laws in connection with the
performance of their respective obligations or the exercise of their respective rights hereunder. 
  
 (b) Lilly’s Obligation. Except to the extent such Damages are due to negligence, gross negligence or willful misconduct by
APBI Holdings, GenuPro, or their officers, directors, employees or agents, Lilly shall defend, indemnify and hold harmless APBI Holdings, GenuPro, and their respective officers, directors, employees and agents against any and all Damages resulting
from or arising out of any breach of: 
  
 (i) any
breach of any representation or warranty made by Lilly in this Agreement or any document executed in connection herewith; 
  
 (ii) the handling, possession, development, marketing, distribution, promotion, sale or use of Product or Compound by Lilly; 

 
 (iii) any product liability or other claim arising out of
any allegation of injury caused by any person’s use of Product or Compound, which Product or Compound is distributed or sold by Lilly or its sublicensees, agents or contractors; 
  

 34 

 (iv) the exercise of any right(s) under the Licensed Patents or GenuPro Know-How, GenuPro
Improvements or GenuPro Manufacturing Know-How, by Lilly or its sublicensees; or 
  
 (v) Lilly’s failure to comply in all material respects with Applicable Laws in connection with the performance of its obligations or
the exercise of its rights hereunder. 
  
 8.2 Notice and
Opportunity To Defend. 
  
 (a)
Notice. Promptly after receipt by a Party hereto of notice of any claim which could give rise to a right to indemnification pursuant to this Article, such Party (the “Indemnitee”) will give the other Party (the
“Indemnifying Party”) written notice describing the claim in reasonable detail. The failure of an Indemnitee to give notice in the manner provided herein will not relieve the Indemnifying Party of its obligations under this Article except
to the extent that such failure to give notice materially prejudices the Indemnifying Party’s ability to defend such claim. 
  
 (b) Defense of Action. In case any action that is subject to indemnification under this Agreement shall be brought against an
Indemnitee and it shall give written notice to the Indemnifying Party of the commencement thereof, the Indemnifying Party shall be entitled to participate and, if it so desires, to assume the defense with counsel of the Indemnifying Party’s
choice, which counsel shall be reasonably satisfactory to such Indemnitee. After notice from the Indemnifying Party to the Indemnitee of its election to assume the defense, the Indemnifying Party shall not be liable to such Indemnitee for any

  

 35 

 
fees of other counsel or any other expenses, in each case subsequently incurred by such Indemnitee in connection with the defense. 
  
 (c) Indemnitee’s Separate Counsel.
Notwithstanding the foregoing, the Indemnitee shall have the right to employ separate counsel and to participate in the defense of such action, and the Indemnifying Party shall bear the reasonable fees, costs and expenses of such separate counsel
if: (i) the use of counsel chosen by the Indemnifying Party to represent the Indemnitee would present such counsel with a conflict of interest, and the Indemnifying Party does not elect to engage new counsel without such a conflict; (ii) the
Indemnifying Party shall not have employed counsel reasonably satisfactory to the Indemnitee to represent the Indemnitee within a reasonable time after notice of the institution of such action; or (iii) the Indemnifying Party shall authorize the
Indemnitee to employ separate counsel at the Indemnifying Party’s expense. 
  
 (d) Settlement. If an Indemnifying Party assumes the defense of such action, no compromise or settlement thereof may be effected by
the Indemnifying Party without the Indemnitee’s written consent, which consent shall not be unreasonably withheld or delayed, unless there is no finding or admission of any violation of law or any violation of the rights of the Indemnitee and
no effect on any other claims that may be made against the Indemnitee. In any event, the Indemnitee and the Indemnifying Party may participate, at their own expense, in the defense of such asserted liability. 
  
 (e) Provision of Documents. If the Indemnifying Party
chooses to defend any claim, the Indemnitee will make available to the Indemnifying Party any books, records or other documents within its control that are necessary or appropriate for such defense; provided, however, any such books, records or
other documents within the control of the 

  

 36 

 
Indemnitee which are made available to the Indemnifying Party hereunder will be held in confidence by the Indemnifying Party in accordance with this
Agreement and will be disclosed by the Indemnitee to the Indemnifying Party only to the extent that such books, records or other documents relate to the claim. 
  

(f) Conduct of Defense. Notwithstanding anything to the contrary in this agreement, the Party conducting the defense of a claim
will (1) keep the other Party informed on a reasonable and timely basis as to the status of the defense of such claim (but only to the extent such other Party is not participating jointly in the defense of such claim), and (2) conduct the defense of
such claim in a prudent manner. 
  
 8.3 Indemnification
Payment. Upon the final, unappealable determination of liability and the amount of the indemnification payment under this Article, the Indemnifying Party will pay such amount to the Indemnified Party in immediately available funds within thirty
(30) business days after such determination. 
  
 8.4 Survival.
The provisions of this Article will survive any termination or expiration of this Agreement. Each Indemnified Party’s rights under this Article will not be deemed to have been waived or otherwise affected by such Indemnified Party’s
waiver of the breach of any representation, warranty, agreement or covenant contained in or made pursuant this Agreement, unless such waiver expressly and in writing also waives any or all of the Indemnified Party’s right under this Article.

  

 37 

 Article 9 
  

Term and Termination 
  
 9.1 Term. The term of this Agreement will begin upon the Effective Date and, unless sooner terminated under this Article, will continue in full
force and effect until the later of (i) the expiration of all Licensed Patents, (ii) the date of expiration of any patent encompassed within GenuPro Improvements or Lilly Improvements claiming inventions that would prevent in whole or in part the
making, using, selling or importing of Product or Compound, or (iii) the date on which APBI Holdings has no remaining royalty payment obligations to Lilly under Section 3.1(b). 
  
 9.2 Termination for Material Breach. Lilly may terminate this Agreement upon material breach thereof by APBI
Holdings, PPD or GenuPro. APBI Holdings, PPD or GenuPro may terminate this Agreement upon material breach thereof by Lilly. The Party seeking to terminate this Agreement shall provide [*] days notice of termination to the defaulting Party,
except in the case of monetary defaults, in which case [*] days notice shall be provided. This Agreement shall be deemed terminated as of the expiration of such [*] day period in the case of monetary defaults or [*] day period
in the case of non-monetary defaults, unless prior thereto the defaulting Party has cured the default. If in the case of a non-monetary default such default is not capable of being cured within such [*] day period, and the defaulting Party is
diligently pursuing the cure of such default, the defaulting party shall be given an additional [*] day period in which to cure such default. If the default remains uncured after such additional period, then this Agreement shall be deemed
terminated. Any failure by APBI Holdings to make any payment to Lilly 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 38 

 required by Article 3, or any development of Dapoxetine by GenuPro for use outside the GenuPro Field, shall be deemed
material breaches of this Agreement. Any development of Dapoxetine by Lilly for use inside the GenuPro Field (other than solely for research purposes as permitted under the licenses granted to Lilly in Article 4) shall be deemed a material breach of
this Agreement. 
  
 Article 10 
  
 Miscellaneous 
  
 10.1 Independent Contractor. It is understood and agreed that
the Parties shall have the status of an independent contractor under this Agreement and that nothing in this Agreement shall be construed as authorization for any of APBI Holdings, GenuPro or PPD, on the one hand, or Lilly, on the other to act as
agent for the other. 
  
 10.2 No Benefit to Others.
The representations, warranties, covenants and agreements contained in this Agreement are for the sole benefit of the Parties and their legal representatives, successors and assigns, and they shall not be construed as conferring any rights to
any Third Person. 
  
 10.3 Amendment. This Agreement may
not be amended, supplemented, or otherwise modified except by an instrument in writing signed by authorized representatives of the Parties. 
  

 39 

 10.4 Entire Agreement. This Agreement constitutes the entire agreement and understanding relating
to the subject matter of this Agreement and supersedes all previous communications, proposals, representations and agreements, whether oral or written, relating to the subject matter of this Agreement. 
  
 10.5 Severability. If any provision of this Agreement is held to be
illegal, invalid, or unenforceable under present or future laws effective while this Agreement remains in effect, the legality, validity and enforceability of the remaining provisions will not be affected thereby. 
  
 10.6 Waiver. Any term or provision of this Agreement may be
waived at any time by the Party entitled to the benefit thereof only by a written instrument executed by such Party. No delay on the part of any Party in exercising any right, power or privilege hereunder will operate as a waiver thereof, nor will
any waiver on the part of any Party of any right, power or privilege hereunder operate as a waiver of any other right, power or privilege hereunder nor will any single or partial exercise of any right, power or privilege hereunder preclude any other
or further exercise thereof or the exercise of any other right, power or privilege hereunder. 
  
 10.7 Notices. All notices required or permitted to be given under this Agreement shall be in writing and shall be deemed given upon receipt if delivered personally or by facsimile transmission
(receipt verified), telexed, mailed by registered or 

  

 40 

 
certified mail (return receipt requested), postage prepaid, or sent by prepaid express courier service, to the Parties at the following addresses (or at such
other address for a Party as shall be specified by the Party; provided, that notices of a change of address shall be effective only upon receipt thereof): 
  
 For GenuPro, PPD and APBI Holdings: 
  
 3151 South 17th
Street 
  
 Wilmington, NC 28412 
  
 Fax No. (910) 772-6951 
  
 Attn: CEO 
  
 With a copy to the attention of the General Counsel at the same address. 
  
 For Lilly:     Eli Lilly and Company 
  
 Lilly Corporate Center 
  
 Indianapolis, IN 46285 
  
 United States of America 
  
 Attention: General Counsel 
  
 10.8 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Indiana, United
States, excluding any choice of law rules which may direct the application of the law of any other jurisdiction. However, the scope, validity and enforceability of any patents encompassed within the scope of this Agreement shall be determined in
accordance with the applicable laws of the countries in 

  

 41 

 
which such patents have issued. In the event of any dispute involving this Agreement, the parties, before seeking any judicial relief, shall submit the
matter to an executive officer of GenuPro, APBI Holdings and PPD and a Lilly executive at the executive director or higher level. If such executives are unable to resolve the matter within fifteen (15) days of the date on which the matter was
referred to them, then either party shall be free to seek judicial relief. Notwithstanding the foregoing, either party may seek immediate judicial relief in the event it believes that it will suffer irreparable injury. 
  
 10.9 Assignability. During the term of this Agreement, none of
the Parties shall assign any benefit or burden under this Agreement without prior written consent of the other Parties, which shall not be unreasonably withheld, except that (i) each Party may assign its rights and obligations under this Agreement
to (A) an Affiliate, (B) to any Person with which it may merge or consolidate, (C) to any Person to whom it may transfer substantially all of its assets to which this Agreement relates, or (D) to any Person which may acquire such Party (including,
in each case, any company created as a new vehicle upon any such merger, transfer or acquisition), and (ii) APBI Holdings, GenuPro or Lilly may transfer any and all of its rights to a sublicensee as provided by this Agreement, and (iii) APBI
Holdings may assign the Licensed Patents to any Person, provided, however, that in the case of (iii) APBI Holdings shall remain liable for all financial obligations to Lilly, including payment of the royalty provided for in Section 3.1(b), and the
assignee shall assume all obligations under this Agreement relating to patent maintenance and cooperation on patent litigation and related matters. 
  

 42 

 10.10 Jointly Prepared. This Agreement will be deemed to have been drafted by the Parties
and will not be construed against any Party as the draftsperson hereof. 
  
 10.11 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be an original, but all of which taken together shall constitute one and the same agreement. It shall not be necessary in
making proof of this Agreement or any counterpart hereof to produce or account for any of the other counterparts. 
  
 10.12 Schedules, Exhibits and Attachments. All schedules, exhibits and attachments referred to herein are intended to be and hereby are
specifically made part of this Agreement. However, if there is a conflict between a term or condition of such schedules, exhibits and attachments and this Agreement, the terms and conditions of this Agreement shall prevail. 
  

 43 

 IN WITNESS WHEREOF, the Parties by their respective authorized representatives, have executed this
Agreement. 
  

			
	Pharmaceutical Product Development, Inc.
		
	By:	 	 
	 	 	

	 	 	Name
	 	 	Title

  

			
	GENUPRO, INC.
		
	By:	 	 
	 	 	

	 	 	Name
	 	 	Title

  

			
	APBI HOLDINGS, LLC
		
	By:	 	 
	 	 	

	 	 	Name
	 	 	Title

  

			
	ELI LILLY AND COMPANY
		
	By:	 	 
	 	 	

	 	 	John C. Lechleiter
	 	 	Executive Vice President
	 	 	Pharma Products/Corporate Development
	 	 	Pharma Products Administration

  

 44 

 EXHIBIT A 
  

LICENSED PATENTS 
  
 [*] 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 45 

 EXHIBIT B 
  

ASSIGNMENT 
  
 WHEREAS Eli Lilly and Company, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana
46285, (hereinafter “Lilly”) is the assignee of all right, title and interest in inventions that are the subject of patents and patent applications (“Applications”) as listed herein below; and 
  
 WHEREAS APBI Holdings, LLC, a wholly-owned subsidiary of
Pharmaceutical Product Development, Inc., and a limited liability company organized under the laws of the State of North Carolina (hereinafter “APBI Holdings”), wishes to acquire the entire interest in Applications; 
  
 NOW, THEREFORE, in consideration of the mutual benefits as set forth
in the Termination and License Agreement, effective December 18, 2003, by and between Lilly and APBI Holdings, and other good and valuable consideration, the receipt of which is hereby acknowledged, Lilly assigns to APBI Holdings, its successors and
assigns, its entire right, title and interest in, to and under Applications, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications applicable to
such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional
patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, and including any, supplementary protection certificates and related
patent term extensions which may be granted for Letters Patent with respect to Applications; all of the above to be held and enjoyed by APBI Holdings for its own use 

  

 46 

 
and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and
entirely as the same would have been held and enjoyed by Lilly had this Assignment to APBI Holdings not been made. 
  
 PATENTS AND PATENT APPLICATIONS ASSIGNED: 
  
 [*] 
  
 Lilly covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

  
 Lilly further covenants and agrees with APBI Holdings that
upon request Lilly will, without further consideration than that now paid, but at the sole expense of APBI Holdings (including reasonable charges for the time of Lilly personnel), provide reasonable (i) cooperation in the further prosecution of
Applications, as for example facilitating the execution of related documents, facilitating communication of facts relating to such inventions or the histories thereof; (ii) cooperation in any interference proceedings, litigation discovery
proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iii) facilitation of the execution and delivery of
any related application papers, affidavits, declarations, assignments, or other related instruments; and (v) facilitation of all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters
Patent and related intellectual property to APBI Holdings or its nominees, in the United States and in all other countries where APBI Holdings may desire to have such inventions, patented. 
  
 IN WITNESS WHEREOF Lilly, by its authorized representative, has
executed this assignment on the date indicated below. 
  

					
			
	  	 	 	 	  
	
	 	 	 	

	 Date
	 	 	 	 John C. Lechleiter

	 	 	 	 	 Executive Vice President

	 	 	 	 	 Pharma Products/Corporate Development

	 	 	 	 	 Pharma Products Administration

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 47 

 UNITED STATES OF AMERICA 
  
 STATE OF INDIANA ) 
                                       ) SS:

 COUNTY OF              ) 
  
 Before me, a Notary Public for              County, State
of Indiana, personally appeared              and acknowledged the execution of the foregoing instrument this
             day of             , 2003. 
  

	
	
	 
	

	 Notary Public

  
 ACKNOWLEDGED
BY APBI Holdings’ authorized representative: 
  

					
			
	  	 	 	 	  
	
	 	 	 	

	 Date
	 	 	 	 Name

	 	 	 	 	 Title

  
 UNITED STATES OF
AMERICA 
  
 STATE OF NORTH CAROLINA ) 
                                        
                 ) SS: 
 COUNTY OF
             ) 
  
 Before me, a Notary Public for              County, State of North Carolina, personally appeared
             and acknowledged the execution of the foregoing instrument this              day of
            , 2003. 
  

	
	
	 
	

	 Notary Public

  

 48

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]